Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
Introduction Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.
Let's personalize your content